Kala Bio (KALA) Change in Acquisitions & Divestments (2021 - 2022)
Kala Bio (KALA) posted Change in Acquisitions & Divestments of $2.0 million for Q3 2022, down 60.0% sequentially from $5.0 million in Q3 2021, and down 60.0% YoY from $5.0 million in Q3 2021.
Kala Bio (KALA) Change in Acquisitions & Divestments (2021 - 2022) Analysis & Trends
Kala Bio has reported Change in Acquisitions & Divestments for 2 years, with the latest figure at $2.0 million in Q3 2022.
- Quarterly Change in Acquisitions & Divestments fell 60.0% year-over-year to $2.0 million in Q3 2022, while the trailing twelve-month figure through Dec 2023 was $2.0 million (down 71.43% YoY) and the FY2023 annual result came in at $10.0 million, up 100.0% from the prior year.
- Change in Acquisitions & Divestments slipped to $2.0 million in Q3 2022 per KALA's latest filing, from $5.0 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $48.2 million in Q1 2021 and troughed at $2.0 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Sep 30, 2021 | 5.00 Mn |
| Sep 30, 2021 | 5.00 Mn |
| Jun 30, 2021 | 23.00 Mn |
| Jun 30, 2021 | 23.00 Mn |
| Mar 31, 2021 | 48.25 Mn |
| Mar 31, 2021 | 48.25 Mn |